Results 31 to 40 of about 90,593 (299)
Scientific Reports, 2021 Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor.
Yu Ueda +8 more
doaj +1 more source
Journal of the American Medical Association (JAMA), 2020 Importance Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial.
S. You +17 more
semanticscholar +1 more source
Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +1 more source
Cytochrome p-450 polymorphisms and response to clopidogrel.
New England Journal of Medicine, 2009 BACKGROUND Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.
J. Mega +10 more
semanticscholar +1 more source
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. [PDF]
PLoS ONE, 2013 BACKGROUND: The efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy.
Tsung-Hsien Lin +9 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj +3 more sources
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
New England Journal of Medicine, 2006 BACKGROUND Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.
Deepak L. Bhatt +25 more
semanticscholar +1 more source
Detection and prediction of clopidogrel treatment failures using longitudinal structured electronic health records [PDF]
arXiv, 2023 We propose machine learning algorithms to automatically detect and predict clopidogrel treatment failure using longitudinal structured electronic health records (EHR). By drawing analogies between natural language and structured EHR, we introduce various machine learning algorithms used in natural language processing (NLP) applications to build models ...
arxiv
Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. [PDF]
PLoS ONE, 2016 OBJECTIVES:In 2009, the FDA issued a warning that omeprazole--a proton pump inhibitor (PPI)--reduces the antithrombotic effect of clopidogrel by almost half when taken concomitantly.
Annie Guérin +6 more
doaj +1 more source
Aspirin and Clopidogrel Resistance [PDF]
Mayo Clinic Proceedings, 2006 Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays.
Richard A. Lange +4 more
openaire +3 more sources